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background: Cardiac troponin is a highly sensitive detector of myocardial injury. Troponin elevation is seen in acute coronary syndromes 
(i.e. Type 1 myocardial infarction [MI]), and in other syndromes not caused by disrupted coronary plaque (i.e. Type 2 MI). Troponin 
elevation is strongly associated with poorer outcomes; however, the difference in risk between Type 1 MI and Type 2 MI is less well 
described.
methods:  In 2006, our Veterans Affairs hospital developed a quality improvement program whereby all admitted and emergency 
department patients with elevated troponin were prospectively evaluated. An attending cardiologist determined if Type 1 MI was present 
and recommended management. We compared the one year mortality risk associated with elevation in troponin either from Type 1 MI or 
Type 2 MI and determined the factors associated with mortality.
Results:  763 patients were evaluated, 99.1% (n=756) men. The majority had coronary disease (n=385, 50.5%) and nearly half had 
diabetes (n=339, 44.4%). Median initial troponin was higher in the Type 1 MI cohort (0.12 ng/mL versus 0.06 ng/mL, p < 0.001) as was the 
prevalence of TIMI risk score greater than 2 (92.5% versus 74.3%, p<0.001) and new changes on the electrocardiogram (27.2% versus 
8.2%, p<0.001). Risk of death at 1 year was 29.0% among Type 1 MI patients versus 42.0% among Type 2 MI patients (relative risk 0.56, 
95% confidence interval [CI] 0.41-0.76, p<0.001). High TIMI risk was not predictive of death by log rank test at 30 days (p=0.06) or at 1 
year (p=0.124). Increasing age (HR 1.03, 95% CI 1.01-1.04 for each year), intensive care unit admission (HR 1.72, 95%CI 1.21-2.45), and 
receiving advanced cardiac life support (HR 5.01, 95% CI 2.98-8.40) were associated with higher mortality. The distribution of these factors 
did not adequately explain the difference in mortality between type 1 and type 2 MI.
conclusion:  In this elderly, male veteran population, elevation in troponin due to a Type 2 MI was associated with higher mortality at one 
year compared to patients with Type 1 MI. Several factors were independently associated with a higher risk of death, but did not elucidate 
the reasons why Type 2 MI carries this higher risk.
